The Latest Cardiac and Vascular News
CHICAGO, Oct. 28, 2024 /PRNewswire/ — Cardiosense, a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation’s 2024 annual Transcatheter Cardiovascular…
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024.
WASHINGTON, Oct. 28, 2024 /PRNewswire/ — MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference…
BORDEAUX, France–(BUSINESS WIRE)–HeartFocus, the revolutionary, AI-enabled heart echo software by data-driven medtech company, DESKi, is proud to announce the launch of the HeartFocus Education app in partnership with Butterfly Network, Inc., (“Butterfly”) (NYSE: BFLY) a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software. The innovative HeartFocus […]
SAN JOSE, Calif.–(BUSINESS WIRE)–Heart Repair Technologies, Inc. (“HRT” or “Company”), a privately-held medical device company specializing in disruptive mitral and tricuspid valve repair technology to resolve heart valve regurgitation in heart failure patients, today announced that David H. Chung has been appointed Chief Executive Officer (CEO), effective as of October […]
WASHINGTON–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe […]
October 28, 2024 (DENVER) – Cleerly, a pioneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in […]
Demonstrated a Reduction of Symptoms with Short Procedural and Recovery Times Leading Coronary Physiology Experts Appointed Co-Principal Investigators for Planned U.S. Early Feasibility Study SANTA CLARA, Calif., Oct. 28, 2024 /PRNewswire/ — VahatiCor, a leader in cardiovascular…
BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial.
DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ — Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ECP™, a novel transvalvular axial flow pump with compressible pump architecture….
